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ABSTRACT We previously demonstrated that a1B-adrener-
gic receptor (AR) gene transcription, mRNA, and functionally
coupled receptors increase during 3% O2 exposure in aorta, but
not in vena cava smooth muscle cells (SMC). We report here that
a1BAR mRNA also increases during hypoxia in liver and lung, but
not heart and kidney. A single 2.7-kb a1BAR mRNA was detected
in aorta and vena cava during normoxia and hypoxia. The a1BAR
5* flanking region was sequenced to 22,460 (relative to ATG 11).
Transient transfection experiments identify the minimal pro-
moter region between 2270 and 2143 and sequence between
2270 and 2248 that are required for transcription of the a1BAR
gene in aorta and vena cava SMC during normoxia and hypoxia.
An ATTAAA motif within this sequence specifically binds aorta,
vena cava, and DDT1MF-2 nuclear proteins, and transcription
primarily initiates downstream of this motif at approximately
2160 in aorta SMC. Sequence between 2837 and 2273 conferred
strong hypoxic induction of transcription in aorta, but not in vena
cava SMC, whereas the cis-element for the transcription factor,
hypoxia-inducible factor 1, conferred hypoxia-induced transcrip-
tion in both aorta and vena cava SMC. These data identify
sequence required for transcription of the a1BAR gene in vascular
SMC and suggest the atypical TATA-box, ATTAAA, may mediate
this transcription. Hypoxia-sensitive regions of the a1BAR gene
also were identified that may confer the differential hypoxic
increase in a1BAR gene transcription in aorta, but not in vena
cava SMC.
Three subtypes of the G protein-coupled a1-adrenergic recep-
tors (AR) designated as the a1A, a1B, and a1D have been
identified (1). Native and cultured rat aorta and vena cava
smooth muscle cells (SMC) express both the a1BAR and
a1DAR subtypes (2, 3). Among a1AR subtypes, a1DAR me-
diates constriction of the rat aorta (4, 5), iliac artery (6), and
arterioles in skeletal muscle (7), whereas the a1BAR signals
constriction of the vena cava (8) and skeletal muscle venules
(7). Sympathetic constriction of arterioles and venules medi-
ated by these vascular a1AR shows a prominent difference in
sensitivity to inhibition by metabolic signals including hypoxia
and acidosis (a1DAR sensitive, a1BAR insensitive), which we
have proposed serves to simultaneously maximize autoregu-
lation and reflex control of venous return (9). Vascular a1AR
also have been shown to couple to additional cellular functions,
including SMC hypertrophy signaled by the a1DAR (10) and
modulation of glucose metabolism in liver and heart mediated
by a1BAR (11, 12). Consistent with this association of the
a1BAR with altered metabolic states, hypoxia (3% O2) tran-
scriptionally up-regulates a1BAR, but not a1DAR, gene ex-
pression in aorta, but not in vena cava SMC, examined in vitro
and in vivo (3). However, it is not known if hypoxic induction
of a1BAR expression is shared by other nonvascular tissues.
Although nothing is known concerning how oxygen levels
regulate transcription of the a1BAR gene, control depends on
trans-acting factors binding to the transcription promoter
region and regulatory elements within the DNA. To begin to
examine transcriptional control, knowledge of gene sequence
upstream to the translation start is required. However, from
the coding region of the rat a1BAR upstream to 2610 (trans-
lation start 11) there is 98% similarity (13–15) but upstream
of 2611 to the end of the reported sequences [GenBank
accession L28752 (14) and D32045 (15)] there is no similarity.
Thus, functional analysis of a1BAR promoter regulation re-
quires resequencing the 59 f lanking region.
There is also significant disagreement in the location of the
site of transcription initiation of the a1BAR in rat cells (14, 15).
Kanasaki and coworkers (15) describe a single transcription
start site at 2173 similar to that reported for the human a1BAR
(16). In contrast, Gao and Kunos (14) proposed the existence
of three different transcription initiation sites in rat liver.
Certain hypoxia-induced genes, under the control of multiple
promoters, have preference for a particular promoter andyor
transcription start site during hypoxia (17). Therefore, it is
important to determine a1BAR sequence required for tran-
scription initiation in both aorta and vena cava SMC, and to
identify whether this changes during hypoxia. Selection of an
alternative promoter for the a1BAR during hypoxia in aorta,
but not in vena cava, could explain differential induction of
transcription by reduced oxygen (3).
Erythropoietin, the primary humoral regulator of increased
erythropoiesis during chronic hypoxemia, is the best charac-
terized mammalian gene for hypoxic regulation of expression
(18). Several cis-elements and their binding factors have been
shown to be essential for hypoxic increase in erythropoietin
transcription in in vitro model systems, notably hypoxia-
inducible factor 1 (HIF-1) (18). The consensus HIF-1 binding
site is present in the a1BAR gene (3). However, it is not clear
whether HIF-1 is involved in the hypoxic up-regulation of
a1BAR in aorta SMC. Although specific and hypoxia-induced
nuclear protein binding to HIF-1 has been demonstrated in all
cell types tested (19), whether HIF-1 or other hypoxia-
inducible enhancers are capable of mediating hypoxic regula-
tion of a1BAR in SMC remains to be determined.
MATERIALS AND METHODS
In Vivo Hypoxia and Cell Culture. Adult rats were exposed to
10% inspired O2 environmental hypoxia for 8 hr as described
previously (3). Preparation and culture of adult rat thoracic aorta
and vena cava SMC primary cultures were performed as de-
scribed (2, 3). For hypoxic exposure, cells were placed in an
O2-regulated incubator (Forma Scientific, Marietta, OH) at 1.5%
or 3% O2, 5% CO2, balance N2 (3).
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RNA Extraction and Detection. Total RNA was extracted as
described (3). Poly(A)1 RNA was selected using Oligotex (Qia-
gen). Northern analysis was performed using 5 mg (aorta, vena
cava) or 2 mg (liver) of poly(A)1 RNA electrophoresed through a
1.2% formamideyformaldehyde agarose gel, transferred to Hy-
bond-N1 membrane (Amersham) by capillary blotting and hy-
bridized with an a1BAR XhoI digested [193 to 1527, relative to
translation start site (ATG) 11] a32P-CTP-labeled probe (Ran-
dom PrimeIt, Stratagene). Prehybridization and hybridization
were performed at 42°C in Hybrisol I (Oncor). Membranes were
then UV crosslinked, washed in 13 standard saline citratey0.1%
SDS 33 30 min at room temperature and 1 3 30 min at 55°C, and
exposed to Kodak X-Omat AR film at 280°C. Size of mRNA was
estimated using RNA Millennium markers (Ambion) and Sigma-
Gel software (Jandel, San Rafael, CA).
RNase Protection Assays (RPA). RPA were performed as
described (3) with one addition. 104 cpm of RNA probe for rat
cyclophilin (Ambion) transcribed by T7 RNA polymerase in
the presence of [a32P]CTP was added to the same RPA
reaction to serve as an internal control. Experiments were
performed to confirm that low O2 did not change cyclophilin
mRNA levels. The riboprobe for determination of transcrip-
tion start site was generated by a BamHIyXhoI digest (2602
to 193) of the a1BAR gene and subcloned into pBluescript SK
(Stratagene) and transcribed by T3 polymerase.
Sequencing. A positive a1BAR clone from a primary screen
of a rat FRTL-5 genomic library was generously provided by
D. M. Perez (Cleveland Clinic). Southern hybridization was
with a BamHIyXhoI (2602 to 193) a1BAR a32P-CTP-labeled
probe (Random PrimeIt, Stratagene). DNA sequencing was
performed in both directions (Sequenase, United States Bio-
chemical).
Plasmid Construction. The PvuII fragment of the a1BAR
genomic DNA (23,500 to 193) was subcloned into the SmaI site
of pGL3basic luciferase reporter vector (Promega) with 59 to 39
orientation (designated 23,500). Promoter deletion plasmids
were obtained by digesting the 23,500 plasmid with various
restriction enzymes to produce the constructs illustrated in Fig.
3A (KpnI 23,200, SacI 22,378, SpeI 22,161, NsiI 21,619, NheI
2999, ApaI 2644, BamHI 2602, BssHII 2270, and SmaI 2127).
The 2248, 2209, 2195, and 2185 constructs were obtained by
digesting the 2270 plasmid with exonuclease III (New England
Biolabs). The reaction was terminated at timed intervals, blunt-
ended with mung bean nuclease, and ligated with T4 ligase (New
England Biolabs). Except as noted, all other constructs were
produced with restriction enzyme digests (New England Biolabs,
sites determined using Wisconsin Package version 9.0, Genetics
Computer Group, Madison WI). Sequential deletions of P2 were
generated using exonuclease III digestion. BglII linkers were
added to both the wild-type and mutated 2262 to 2242 oligo-
nucleotides, which then were subcloned into the BglII site of
pGL3basic and pGL3promoter luciferase reporter vectors. The
2860 to 2724 plasmid was made with PCR amplification using
primers to a1BAR sequence (primers: 2860 to 2840 and 2724
to 2744) and BglII linkers. The PCR product was agarose
gel-purified (GeneClean, Bio101) and subcloned in both orien-
tations into pGL3 promoter. The HIF-1 oligonucleotide (se-
quence given below) was subcloned into pGL3promoter. Multiple
copies of the HIF-1 oligonucleotide (wild type and mutated) were
generated as described (20). All constructs were purified by
double CsCl gradient centrifugation and verified by sequencing.
Transfection and Luciferase Assay. Cells in passage four
were split onto 6-well plates (Falcon) and transfected at 100%
confluence for 6 hr with 5 mgywell of luciferase reporter
plasmid and 1 mgywell of b-galactosidase normalization plas-
mid (Promega) using calcium phosphate (21). After two
washes, cells were exposed to normoxia or hypoxia, and
extracts were prepared 12 hr later. Luciferase analysis was
performed using a luciferase assay kit (Promega), and activity
was determined with a Wallac Microbeta 1450 countery
luminometer. All experiments were performed in duplicate,
with a minimum of three replications.
The following control experiments were conducted: Similar
data to those reported were obtained (i) when conducted in the
absence of b-galactosidase cotransfection and normalized to
protein content, (ii) using DOTAP [N-(1-(2,3-dioleoy-
loxy)propyl)-N,N,N-trimethylammonium methyl sulfate]
(Boehringer Mannheim) instead of calcium phosphate, and
(iii) b-galactosidase activity was not altered during hypoxia. In
addition, we verified in aorta (with similar results in vena cava)
that the activity of the luciferase vectors were sufficient to
study increases and decreases in transcriptional activity. When
luciferase activity was normalized to pGL3basic (luciferase
vector lacking a promoteryenhancer), pGL3promoter (simian
virus 40 promoter) activity was 55-fold 6 3-fold greater and
pGL3control (simian virus 40 promoter and enhancer) was
340-fold 6 41-fold greater than pGL3basic alone.
Gel-Shift Analysis. Nuclei were isolated from approximately
4 3 107 aorta, vena cava, or DDT1MF-2 cells at 80% conflu-
ence (20). Sequences for the oligonucleotides used were as
follows: 2262 to 2242 (59-TGGACCATTAAACTCGAG-
CCG-39), 2262 to 2242 mutated (59-TGGACCACT-
CAGCTCGAG CCG-39) (Life Technologies, Grand Island,
NY); HIF-1 (59-CAGGCGACGTGCTGCCGGGT-39), HIF-1
mutated (59-CAGG CGAAAAGCTGCCGGGT-39) (Macro-
molecular Resources, Fort Collins, CO), consensus cAMP
response element binding (59-AGAGATTGCCTGACGTCA-
GAGAGCTAG-39) (Promega); the sequence unrelated oligo-
nucleotide for both gel-shifts (see Figs. 3A and 5) was (59-
CGAACTGATGGTCAAGGTGATTCA-39) (Life Technol-
ogies). The double-stranded 2262 to 2242 and HIF-1 probes
were end-labeled with [g32P]ATP and gel-purified on a 5%
nondenaturing polyacrylamide gel. Ten micrograms of nuclear
protein was incubated with 0.5 ng of 2–5 3 104 cpm of labeled
probe in a 20-ml reaction mixture containing 4 mg of polydI-dC,
10 mM Hepes at pH 7.9, 10% glycerol, 2% Ficoll-400, 40 mM
NaCl, and 2 mM DTT. The binding reactions were carried out
on ice for 30 min, and DNA-protein complexes were separated
on a 5% nondenaturing polyacrylamide gel. For competition
experiments, 10- to 200-fold molar excess of unlabeled an-
nealed oligonucleotides were added to the binding reaction
mixtures before addition of the labeled probes.
RESULTS
Previously, we showed that 8 hr of low O2 produced a 2- to
5-fold increase in a1BAR mRNA, protein, and functional
receptor response in aorta, but not in vena cava SMC (3). To
determine whether this also occurs in other tissues, rats were
exposed to 10% inspired O2 (hypoxic hypoxia) for 8 hr. Tissues
were harvested, RNA extracted, and RPAs performed. a1BAR
mRNA levels were normalized to cyclophilin levels after
confirming that cyclophilin levels were unchanged during
hypoxic exposure (data not shown). a1BAR mRNA increased
40 6 28% in liver (P 5 0.03) and 30 6 7% in lung (P 5 0.02)
during hypoxia but not in heart or kidney.
In contrast to a1BAR mRNA in liver that has been pur-
ported to be under the control of three promoters (14),
Northern analysis revealed that aorta and vena cava express
only one a1BAR mRNA approximately 2.7 kb in size (Fig. 1A).
It is thus likely only one promoter and transcription start site
is used in normoxic vascular SMC. Hypoxia (3%, 8 hr) did not
change a1BAR mRNA size (data not shown), suggesting that
the same promoter and transcription start site direct expres-
sion of the a1BAR during hypoxia. The size of the a1BAR
mRNA, exclusive of the 59 untranslated end, has been esti-
mated at approximately 2.3 kb (14). Therefore, these data
suggest that the transcription start site resides between 2200
and 2600 bp.
To define the minimal promoter area used by vascular SMC,
a 3.5-kb PvuII-digested fragment was isolated and partially






















sequenced. The results confirm the sequence reported by Gao
and Kunos (14) and extend it further upstream (Fig. 1B).
Restriction enzyme and exonuclease III digests were per-
formed on a construct containing 3.5 kb of a1BAR sequence (59
to ATG) that was subcloned into a luciferase vector lacking
promoter (pGL3basic), to functionally define sequence within the
59 region required for a1BAR gene transcription. The constructs
shown in Fig. 2A were transiently transfected into aorta SMC, and
luciferase and b-galactosidase activity was measured. Sequence
between 2270 and 2248 is required for a1BAR gene transcrip-
tion in aorta (Fig. 2A). These same constructs were transfected
into vena cava SMC and yielded a similar pattern, including the
abrupt loss of transcription with deletion of sequence down-
stream of 2270 (data not shown). To better identify a minimal
promoter region and remove the putative P1 region identified in
liver (14), we constructed a plasmid subcloned into pGL3basic
that ranged from 2270 to 2143. This construct showed robust
transcriptional activity with an 880 6 75% increase in luciferase
activity as compared with the promoterless vector. This suggests
that we have functionally identified a promoter region within the
a1BAR gene that is used in aorta and vena cava SMC. This data
also corroborates other previously identified transcription start
sites in rat (15) and human (16) at approximately 2175. A similar
pattern was obtained for the same constructs transfected into
aorta SMC and exposed to hypoxia, where deletion constructs
downstream of 2270 once again resulted in loss of transcription
(data not shown). These data strengthen the conclusion from our
Northern data (Fig. 1A) that the same promoter and transcrip-
tion start site is used in vascular SMC during hypoxia.
Although these findings do not support the use in SMC of the
putative promoters P1, P2, and P3 previously hypothesized to
function in the rat liver (14), we made constructs surrounding
these regions and transiently transfected them into aorta (Fig. 2B)
and vena cava SMC (data not shown) during normoxia (Fig. 2B)
and hypoxia (data not shown) to further test this hypothesis.
Minimal transcriptional activity, as compared with the constructs
that ranged from 193 to 2270 and further upstream, was evident
for all but one construct. The region from 2746 to 2273 showed
robust transcriptional activity, whereas 2659 to 2273 showed
virtually none. Gao and Kunos (14) also reported that sequence
between 2813 and 2675 was capable of driving transcription in
human liver Hep3B cells and hamster DDT1MF-2 cells. However,
loss of this sequence in our full-length deletion analysis resulted
in no loss of transcriptional activity (Fig. 2A). Therefore, it
appears that, at least in these transfection studies, in the context
of a1BAR sequence ranging from 23,500 to 193, this region does
not drive endogenous transcription in vascular SMC to a signif-
icant degree although its involvement cannot be conclusively
ruled out with this data.
Based on the data from our full-length deletion analysis (Fig.
2A), we focused on the sequence between 2270 and 2248 that
is critical for a1BAR gene transcription in vascular SMC. An
ATTAAA motif within this sequence has been shown to function
as an atypical TATA-box in the epidermal growth factor gene
(22). Gel-shift analyses were conducted to test whether this motif
was capable of binding aorta and DDT1MF-2 SMC nuclear
proteins. The migration of a radiolabeled double-stranded oli-
gonucleotide corresponding to sequence within 2262 to 2242
was slowed upon incubation with aorta SMC nuclear proteins
(Fig. 3A). The formation of these complexes was competitively
inhibited in the presence of 103 and to a greater extent with 503
excess unlabeled 2262 to 2242 oligonucleotide. A double-
stranded 2262 to 2242 oligonucleotide mutated to ACTCAG
was used to determine if these specific complexes were binding to
the ATTAAA motif. This mutated oligonucleotide was not
capable of competing aorta nuclear protein binding. The pattern
was similar in DDT1MF-2 (Fig. 3A) and vena cava SMC, as well
as during hypoxia (data not shown). These results indicate that
protein(s) are binding to the ATTAAA motif and perhaps,
similar to epidermal growth factor, this sequence acts as an
atypical TATA-box. A putative cap site is located 53 bp (2202)
39 to ATTAAA (as determined using the transcription factor
FIG. 1. Cultured aorta and vena cava SMC express a single a1BAR
mRNA whereas liver expresses two a1BAR mRNA. (A) Northern analysis
using a radiolabeled probe that spanned 193 to 1527 was performed on
5 mg (cultured aorta and vena cava SMC) or 2 mg (liver) poly(A)1 RNA.
(B) Sequence of the 59 region of the a1BAR gene confirmed sequence
previously reported (14) (22,050 to 21,947) and extended it further
upstream to 22,460 [all orientations relative to met (ATG) 11].
FIG. 2. Sequence between 2270 and 2248 is essential for tran-
scription of the a1BAR gene. (A) Sequential restriction digest and
exonuclease III deletion of the 59 region of the a1BAR gene subcloned
in the pGL3basic (luciferase vector lacking a promoter) were obtained
and transiently transfected in aorta SMC. (B) Constructs, designed
based on three previously reported promoters, P1, P2, and P3 (14),
were made using restriction enzyme and exonuclease III digestion.
Duplicate transient transfection assays for each construct described
above were performed in aorta SMC (n 5 3). Data were normalized
to b-galactosidase activity and presented as mean 6 SEM and a
percentage of pGL3basic. Broken line at 100% indicates no change
from pGL3basic luciferase activity.






















binding data set in the Wisconsin Package version 9.0, Genetics
Computer Group), also consistent with the ATTAAA motif
serving as an atypical TATA-box. In addition, transcription
initiation from this region would yield a 59 untranslated segment
of approximately 200 bp, confirming our Northern data (Fig. 1A).
To ascertain the a1BAR gene transcription start site, we
performed RPAs using a probe to sequence ranging from
2602 to 193 (Fig. 3B). The 290-bp protected fragment that
resulted upon analysis of liver and kidney total RNA suggests
that the major transcription start site for the a1BAR gene is at
approximately 2200 in these tissues. In aorta, the 250-bp
protected species corresponds to an a1BAR gene transcription
start site at approximately 2160 (Fig. 3B).
The preceding results indicate that the a1BAR promoter lies
between 2270 and 2143 and likely encompasses the atypical
TATA-box sequence, ATTAAA located at 2256. This same
promoter appears to be used by aorta and vena cava SMC and
remains unchanged during low O2 exposure. We next wanted to
determine cis-elements within the a1BAR gene that influence this
promoter and confer increased transcription during low O2 (3).
Transcriptional activity of the luciferase vectors pGL3basic or
pGL3promoter alone were unaffected by hypoxia, as expected for
these controls (Fig. 4B). Hypoxia increased transcriptional activ-
ity of the 2602 to 193 construct, and this was lost with the 2270
to 193 and 2127 to 249 constructs (Fig. 4B). A consensus HIF-1
transcription factor binding site at 2164 and its corresponding
constitutive binding partner CACAG (23) at 2334 are present in
the 59 region flanking the a1BAR coding sequence (Fig. 4A). The
loss of this CACAG in the 2270 to 193 construct may attenuate
activity elicited by HIF-1 (23). However, unlike endogenous
a1BAR sensitivity to hypoxia (3), use of 3% O2 may not have been
low enough to activate detectable increases in transcription in
these reporter assays (24). Likewise, cAMP levels increase during
hypoxia (25), and there are four putative AP2 sites between 2602
and 2270 (Fig. 4A) that could link increases in cAMP to the
hypoxic increase in transcription of the 2602 to 193 construct
and the a1BAR gene.
Strong hypoxia-induced transcription in aorta SMC was con-
ferred by the 2837 to 2273 construct, with a 700% increase in
luciferase activity. This induction was lost with the 2746 to 2273
construct. In contrast, the 2837 to 2273 construct transfected
FIG. 3. A specific nuclear protein(s) from aorta SMC and
DDT1MF-2 binds to an oligonucleotide (2262 to 2242) surrounding the
ATTAAA motif and the a1BAR gene transcription start site is located
between 2160 and 2200. (A) Representative gel-shift analysis was
performed using an a32P-ATP radiolabeled double-stranded oligonucle-
otide (2262 to 2242) and 10 mg of nuclear protein isolated from cultured
aorta SMC or DDT1MF-2 cells. Competition was performed using
unlabeled oligonucleotide and an oligonucleotide mutated at the AT-
TAAA motif to ACTCAG. (B) Representative RPA to determine
transcription start site. The 765-bp riboprobe ranged from 2602 to 193
and included additional pBluescript vector sequence. It encompassed the
minimal promoter region we identified and the ATTAAA motif. Probe
digested lane consisted of 80 mg tRNA hypbridized with probe. Other
tissueycells used and amount of total RNA were as indicated.
FIG. 4. Specific hypoxic regulation exists for the a1BAR gene. (A)
There is a consensus HIF-1 binding site at 2164 and its companion
constitutive element (CACAG) at 2334. a1BAR sequence between
2837 and 2746 contains putative binding sites for a number of
transcription factors including AP1, NFkB, and AP2 (as defined by the
transcription factor data set in the Genetics Computer Group pro-
gram), which have been implicated in the control of hypoxic up-
regulation of other genes (18). (B) Characterization of induction of
transcriptional activity in aorta SMC by 3% O2 exposure using
pGL3basic for all except 2860 to 2724 and 2724 to 2860, which were
subcloned into pGL3promoter. (C) One, two, four, or eight copies of
a1BAR sequence surrounding the putative consensus HIF-1 binding
site (GACGTGCT) or one or eight copies of an oligonucleotide
mutated at base pairs critical for HIF-1 binding (22) (GAAAAGCT)
were subcloned into pGL3promoter. For both B and C, constructs were
transiently transfected in duplicate into aorta SMC. After 12 hr of low
O2 (3% or 1.5% O2) or 21% O2, cells were harvested and luciferase
and b-galactosidase activity were determined. Data are normalized to
b-galactosidase activity and expressed relative to pGL3basic (2simian
virus 40 promoter) or promoter (1simin virus 40 promoter) activity
(dependent on vector backbone) and as a percent of time-matched
normoxic controls, mean 6 SEM, n 5 3 for all constructs.






















into vena cava SMC increased transcription less (240%). Se-
quence between 2837 and 2746 contains putative AP1, NFkB,
and AP2 sites for binding transcription factors that have been
implicated in mediating hypoxia-induced transcription of other
genes (18). It is possible that these trans-acting factors or other
cis-elements within this region are responsible for conferring the
hypoxic increase in transcription of a1BAR in aorta, liver, and
lung, but not in vena cava, kidney, and heart. To further test the
hypoxia-inducing capacity of the 2837 to 2746 region, we
subcloned this segment into pGL3promoter (2860 to 2724).
There was minimal hypoxia-induced transcription off of this
region when oriented in the forward direction. However, hypoxia
doubled luciferase activity when this region was present in the
reverse orientation (2724 to 2860) (Fig. 4B). While these data
suggest that this region is capable of binding trans-factors that
increase transcription in aorta but less so in vena cava SMC during
hypoxia, protein–protein interactions may extend between this
region and 2724 to 2273 that confer the more robust hypoxia
induction.
Because the HIF-1 binding site is essential for hypoxic induc-
tion of the erythropoietin gene (18), we examined whether HIF-1
alone can confer transcriptional increases in a1BAR mRNA. One,
two, four, or eight copies of the a1BAR HIF-1 binding site,
GACGTGCT, and 6 bp flanking this region in both directions,
were subcloned into pGL3promoter, transfected into aorta SMC
and assessed for luciferase activity during hypoxia. Because
mutation of this binding site to GAAAAGCT has been shown to
completely attenuate HIF-1 binding (23), we also subcloned one
and eight copies of the mutated oligonucleotide into
pGL3promoter. Both 3% and 1.5% hypoxia-induced transcrip-
tion at successively greater magnitudes as the number of HIF-1
copies was increased (Fig. 4C). This induction was lost when the
HIF-1 binding site was mutated. This pattern also was seen in
vena cava cells (data not shown). Therefore HIF-1 is capable of
increasing a1BAR transcription in an O2 tension-dependent man-
ner in both cell types.
To test whether hypoxia induces binding to the HIF-1
oligonucleotide, we performed gel-shift analysis. The double-
stranded HIF-1 oligonucleotide was radiolabeled and incu-
bated with aorta nuclear protein from control cells and cells
exposed to 4 hr of either 3% or 1.5% O2. A constitutive binding
(Fig. 5, bracketed region) could be competed away almost
completely with 2003 excess unlabeled oligonucleotide (data
not shown). In addition, this binding was competed by 1003
excess cAMP response element binding (CREB) oligonucle-
otide, similar to what others have shown for the erythropoietin
HIF-1 (26), but not by an oligonucleotide of unrelated se-
quence (data not shown). This binding was not competed by
the mutated HIF-1 oligonucleotide because cis-sequence for
CREB and HIF-1 overlap, and the mutation also inhibits
CREB binding (Fig. 5). Three percent O2 induced a new
binding activity that was further increased by 1.5% O2 (Fig. 5,
arrows). This binding was competed by 103 and to a greater
extent by 503 excess unlabeled oligonucleotide. A similar
pattern was obtained in DDT1MF-2 SMC (data not shown).
Therefore, the data in Figs. 4 and 5 suggest that low O2 induces
specific binding to the HIF-1 element that can confer a
functional increase in a1BAR gene transcription.
DISCUSSION
We have identified sequence required for transcription initi-
ation of the a1BAR and regulation of transcription by hypoxia-
responsive cis-acting elements in vascular SMC. A minimal
promoter region was located between 2270 and 2143, and
sequence between 2270 and 2248 was required for transcrip-
tion initiation in vascular SMC, leading to the production of a
single 2.7-kb transcript that was unchanged by hypoxia. This
2270 to 2143 sequence is 92% similar with the human a1BAR,
and a putative cap site is present in both sequences at 2202,
and RPAs suggest that the major transcription start site resides
between 2160 and 2200 for the a1BAR in aorta, liver, and
kidney. Within this sequence, a putative atypical TATA-box,
ATTAAA, bound nuclear proteins from aorta, vena cava, and
DDT1MF-2 SMC. While this binding activity was unaffected
by hypoxia, sequence between 2837 to 2273, but not 2746 to
2273, mediated hypoxic increase in transcription in aorta but
not vena cava SMC. On the other hand, an oligonucleotide
containing the hypoxia-sensitive transcription factor HIF-1
element surrounded by a1BAR sequence demonstrated both
constitutive and hypoxia-induced binding activities, and con-
ferred hypoxic induction of transcription in aorta, vena cava,
and DDT1MF-2 SMC.
The 2.7-kb rat a1BAR transcript is widely expressed (1), is
the only mRNA found in heart (27, 28), brainstem, cerebral
cortex, kidney, and aorta (28), and was the only transcript we
detected in aorta and vena cava SMC. A 2.8-kb a1BAR mRNA
is also the only transcript reported for human tissues (16).
However, three additional transcripts (2.3, 3.3, and 4.0 kb)
have been described for the rat a1BAR in certain tissues (14,
27–29). The existence of multiple promoters and transcription
start sites has been proposed to account for this reported
heterogeneity of rat a1BAR transcript size (14). However, a
prominent transcription start site was identified at 2178 for
the a1BAR gene in four different human tissuesycells (16).
Likewise, Kanasaki and coworkers (15) described a single
transcription start site at 2173 for the a1BAR in the rat
FRTL-5 thyroid cell line. In contrast, Gao and Kunos (14) have
proposed that rat liver uses three a1BAR transcription start
sites (254, 2443, and 21,107). Our Northern data, transcrip-
tion reporter assays, and RPAs indicate that aorta and vena
cava SMC transcribe a1BAR from a single start site that is
unchanged during hypoxia. Our evidence in rat for the 2.7-kb
size of the a1BAR transcript and location of the start site
around 2160 to 2200 bp is consistent with Kanasaki et al. (15)
and Ramarao et al. (16). Furthermore, our results identify the
minimal promoter region (2270 to 2143) and sequence (2270
and 2248) required for transcription initiation.
One possible explanation for the difference between our
results in rat SMC and those reported for rat liver (13, 14, 30)
is tissue specificity. It has been suggested that genes, such as the
a1BAR, which contribute to control of liver metabolism,
contain alternative liver-specific promoters (31). However, the
FIG. 5. Binding to the a1BAR HIF-1 sequence is induced during
hypoxia in aorta SMC. A radiolabeled double-stranded oligonucleo-
tide surrounding the a1BAR consensus HIF-1 binding site was tested
for binding with nuclear protein isolated from control aorta SMC or
cells exposed to 4 hr of 3% or 1.5% O2. Competition was performed
with unlabeled oligonucleotide and an oligonucleotide mutated at
critical HIF-1 binding sites. Arrows indicate inducible binding, and
bracketed area indicates constitutive binding.






















proposed use of multiple promoters and transcription start
sites in rat liver may be specific to this species, because the
a1AAR, rather than the a1BAR, is expressed in rabbit, dog, and
human liver (32) and has been detected only as a single
transcript (33). Gao and coworkers (30) also have reported
that the transcription start site corresponding to the single
2.7-kb a1BAR mRNA in rat heart is at a different, but
unspecified, location from the transcription start site they
describe for this transcript in rat liver. In addition, Gao and
Kunos (14, 30) performed their promoter studies using a rat
a1BAR gene transfected into heterologous human Hep3B and
hamster DDT1MF-2 cell lines so perhaps some species–species
interaction is occurring, which complicates interpretation.
Several observations suggest that the ATTAAA motif, located
at 2256, is a functional atypical TATA-box within the a1BAR
gene promoter in SMC. Loss of sequence, including this motif,
results in attenuation of transcriptional activity, and proteins bind
specifically to this motif in aorta, vena cava SMC, and DDT1MF-2
cells (Figs. 2 and 3). Four other possible transcription start sites
just upstream of 2178 were identified using primer extension and
PCR analysis, suggesting that the location of the transcription
start site may lie somewhere between 2178 and 2227 in the
human a1BAR gene (16). There is a potential cap site within 53
bp downstream (2202) of ATTAAA, and our RPAs identified
the region between 2160 and 2200 as being the site of tran-
scription initiation (Fig. 3), which is consistent with the hypothesis
that the ATTAAA motif may function as an atypical TATA-box.
Importantly, this motif is capable of mediating transcription in
other genes, including type IV collagenase (34) and epidermal
growth factor (22). Furthermore, the a1BAR region from 2270
to 2143 is 59% G1C-rich, which is inconsistent with the use of
an Sp1-like promoter.
We have identified a region of the a1BAR gene that is induced
by hypoxia in aorta, but not in vena cava SMC, which may be
important in the hypoxic increase of a1BAR in arteries (Fig. 4).
This region between 2837 and 2746 contains consensus se-
quences for known hypoxia-sensitive transcription factors: AP1,
NFkB, and AP2. As well, there are four AP2 sites further
downstream, and we provide evidence (Fig. 4) that additional
downstream sequence is likely involved in the hypoxic response
(Fig. 4B). cAMP increases in aorta SMC during hypoxia (25), and
increased cAMP levels promote a1BAR gene transcription (26).
Therefore, one possible hypothesis is that a hypoxia-induced
increase in cAMP may be mediating at least part of the increase
in a1BAR gene transcription. Increased cAMP appears to mediate
the hypoxic up-regulation of lactate dehydrogenase A (25, 35), and
O2 sensing by cells has been suggested to involve cAMP-activated
protein kinase A (26). However, this hypothesis would require that
cAMP levels be differentially regulated in arterial versus venous
SMC, and to our knowledge, this has not yet been examined. It has
been shown that unlike aorta SMC, cAMP levels decrease in
bovine endothelial cells during hypoxia (36) and cAMP activity
decreased in rat lung but not in rat liver after 24 hr of hypoxia (37).
Although a smaller hypoxic increase in cAMP levels in venous
SMC may explain the smaller 240% increase in the 2837 to 2746
a1BAR construct in vena cava SMC compared with the 700%
increase evident in aorta SMC (Fig. 4B), additional transcriptional
regulatory mechanisms probably are involved. We also identified
a potential role for the ubiquitous hypoxic transcription factor
HIF-1 element in the hypoxic increase in a1BAR gene transcrip-
tion. Consistent with other cell types (19), HIF-1 binding activity
was induced at both 3% and to a greater degree at 1.5% O2.
However, these experiments did not reveal a substantial difference
in the ability of HIF-1 to drive a1BAR gene transcription in aorta
and vena cava SMC during hypoxia.
Although the significance of selective hypoxic increase in
arterial SMC a1BAR expression, which we have demonstrated
occurs in vivo (3), remains to be determined, several possibil-
ities are noteworthy. Local metabolic regulatory mechanisms,
including reduced O2 and acidosis, inhibit a2DAR and a1DAR
constriction of blood vessels, whereas a1BAR constriction is
insensitive (9). Thus, an increase in a1BAR density in an
ischemic tissue could impair autoregulatory metabolic inhibi-
tion of sympathetic constriction, placing the tissue at risk for
excess sympathetic constriction. In chronic systemic hypox-
emia, increased a1BAR density could favor preservation of
sympathetic SMC tone and oppose hypotension. Stimulation
of a1BAR in cardiomyocytes increases glucose uptake, phos-
phofructokinase activity, and glucose-6-phosphate dehydro-
genase mRNA (12), and in liver increases glycogenolysis (11).
Consequently, during prolonged hypoxia, an increase in
a1BAR may sustain or increase adrenergic constriction and at
the same time also increase metabolic capacity of certain cells.
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